Zobrazeno 1 - 10
of 71
pro vyhledávání: '"EJ Alegre Del-Rey"'
Publikováno v:
Section 6: Education and research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a48be22b56433c8b774e57eafcae3c7
https://doi.org/10.1136/ejhpharm-2023-eahp.339
https://doi.org/10.1136/ejhpharm-2023-eahp.339
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c248069978e5259887d141f1fdf981f4
https://doi.org/10.1136/ejhpharm-2022-eahp.177
https://doi.org/10.1136/ejhpharm-2022-eahp.177
2SPD-033 Evaluation of docetaxel in low and high burden metastatic hormone sensitive prostate cancer
Autor:
Marina Sánchez-Hidalgo, C Alarcon De La Lastra-Romero, Mdp Briceño-Casado, Gil-Sierra, B De La Calle-Riaguas, EJ Alegre-Del Rey, M Dominguez-Cantero
Publikováno v:
Section 2: Selection, procurement and distribution.
Background and importance Addition of docetaxel to hormonal treatment in low and high burden metastatic hormone sensitive prostate cancer (mHSPC) has raised important issues. There are studies suggesting increased overall survival (OS) in high burden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54a2d3d027da7bb7071a3b3255d7e162
https://doi.org/10.1136/ejhpharm-2021-eahpconf.16
https://doi.org/10.1136/ejhpharm-2021-eahpconf.16
Autor:
FJ Salmeron Navas, M Dominguez Cantero, EJ Alegre-Del Rey, Silvia Fénix-Caballero, EM Barreiro-Fernandez, C Moreno-Ramos
Publikováno v:
Section 1: Introductory statements and governance.
Background and importance ALK gene mutation occurs in 3–5% of patients with non-small cell lung cancer (NSCLC). Brigatinib and alectinib are potent ALK tyrosine kinase inhibitors, indicated in NSCLC. Aim and objectives The aim of this study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::017174bafb51a17a40e8399c644d7cc4
https://doi.org/10.1136/ejhpharm-2021-eahpconf.2
https://doi.org/10.1136/ejhpharm-2021-eahpconf.2
Autor:
B De La Calle-Riaguas, Gil-Sierra, Mdp Briceño-Casado, Marina Sánchez-Hidalgo, C Alarcon De La Lastra-Romero, EJ Alegre-Del Rey, M Dominguez-Cantero
Publikováno v:
Section 2: Selection, procurement and distribution.
Background and importance A greater benefit was suggested with early treatment with remdesivir against COVID-19. Aim and objectives To develop a systematic review and methodological interpretation of subgroup analyses according to timing of use of re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8230609fb65b91b338fa15fd2d7812a1
https://doi.org/10.1136/ejhpharm-2021-eahpconf.14
https://doi.org/10.1136/ejhpharm-2021-eahpconf.14
Autor:
B De La Calle-Riaguas, Gil-Sierra, Mdp Briceño-Casado, C Alarcon De La Lastra-Romero, Silvia Fénix-Caballero, EJ Alegre-Del Rey, M Dominguez-Cantero, Marina Sánchez-Hidalgo
Publikováno v:
Section 2: Selection, procurement and distribution.
Background and importance There are studies (subgroup analyses) suggesting a lack of benefit for daratumumab drug combinations in patients with untreated multiple myeloma (MM) and hepatic impairment (HI). Aim and objectives To conduct a systematic se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78691027999223c3c3b24f12eaa84ab3
https://doi.org/10.1136/ejhpharm-2021-eahpconf.17
https://doi.org/10.1136/ejhpharm-2021-eahpconf.17
Autor:
C Martínez Díaz, EM Barreiro Fernandez, EJ Alegre-Del Rey, FJ Salmeron Navas, M Dominguez Cantero, S. Fénix Caballero
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance The SARS-CoV-2 pandemic could have changed the clinical management of cancer patients because of travel restrictions, overloading of hospital systems and disruption of treatment. Lung cancer patients constitute a vulnerable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0090f1368b02ccbf0f2c2319dd0d6ac4
https://doi.org/10.1136/ejhpharm-2021-eahpconf.128
https://doi.org/10.1136/ejhpharm-2021-eahpconf.128
Autor:
Silvia Fénix-Caballero, M Dominguez-Cantero, B De La Calle Riaguas, EJ Alegre-Del Rey, Vicente Gimeno-Ballester, Mdp Briceño Casado
Publikováno v:
Section 2: Selection, procurement and distribution.
Background and importance Multiple therapeutic alternatives are used in untreated metastatic squamous non-small cell lung cancer (umSNSCLC). Paclitaxel–carboplatin–pembrolizumab combination (PC-pembrolizumab) has recently been authorised for this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bdde925c902f4e3d01d73f449ee96ef
https://doi.org/10.1136/ejhpharm-2021-eahpconf.15
https://doi.org/10.1136/ejhpharm-2021-eahpconf.15
Autor:
Silvia Fénix-Caballero, M Dominguez Cantero, EJ Alegre-Del Rey, Mdp Briceño Casado, Gil-Sierra
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Erenumab, fremanezumab, galcanezumab and eptinezumab are monoclonal antibodies targeting the calcitonin gene related peptide pathway (anti-CGRP), used as preventive treatment in chronic migraine (CM). Aim and objectives To e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c2235e90db4e22dd932d0b89d899733
https://doi.org/10.1136/ejhpharm-2020-eahpconf.233
https://doi.org/10.1136/ejhpharm-2020-eahpconf.233
1ISG-004 Economic comparison of therapeutic alternatives for firstline treatment of multiple myeloma
Autor:
EJ Alegre-Del Rey, Gil-Sierra, Mdp Briceño-Casado, M Dominguez-Cantero, Silvia Fénix-Caballero
Publikováno v:
Section 1: Introductory Statements and Governance.
Background and importance A combination of daratumumab, bortezomib, melphalan and prednisone with daratumumab for maintenance (DVMP-D) has been authorised as a firstline treatment for patients with newly diagnosed multiple myeloma who are ineligible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae066d554989a03b66cd55a8bb621f8c
https://doi.org/10.1136/ejhpharm-2020-eahpconf.4
https://doi.org/10.1136/ejhpharm-2020-eahpconf.4